To expedite its push into mobile health, Yardley, Pennsylvania-based StayWell announced today that it has acquired the mobile health portion of Silicon Valley-based MedHelp, which includes several consumer-facing mobile health apps.
FDA is committed to expanding access to safe and effective treatment options for patients with rare, debilitating, and sometimes fatal diseases. These patients face unique medical challenges. Sometimes there isn’t an FDA-approved drug to adequately address the needs of a patient with a rare disease. Therefore, the agency needs to take new steps to enable more patients with unmet needs to get access to promising treatments prior to full FDA approval.
Amgen and Basel, Switzerland-based Novartis announced they have expanded their collaboration with the Banner Alzheimer’s Institute (BAI) to launch a new clinical trial in Alzheimer’s.
Shockwave Medical reported $35 million in new financing, an extension of the company’s previously announced $45 million Series C financing. New investor Fidelity Management & Research Company participated, along with certain funds and accounts advised by T. Rowe Price Associates, Inc., a returning investor.
The debate explores whether food taxation is an indispensable strategy to correct obesity trends, or whether there should be other ways of approaching the problem.
Regeneron and Sanofi have unveiled positive new data from a late-stage trial investigating the biologic dupilumab in adults and adolescents 12 years of age and older with severe, steroid dependent asthma.
"Our study suggests that estrogen treatment after menopause protects the memory that is needed for short-term cognitive tasks from the effects of stress," said Alexandra Ycaza Herrera, the study's lead author and a researcher at the USC Leonard Davis School of Gerontology.
A vaccine combining centralized ancestral genes from four major influenza strains appears to provide broad protection against the dangerous ailment, according to new research by a team from the Nebraska Center for Virology.
In October, the European Medicines Agency (EMA) granted PRIME designation to GSK2857916 for the treatment of relapsed and refractory multiple myeloma patients whose prior therapy included a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody. GSK2857916 is an anti B-cell maturation agent (BCMA) monoclonal antibody-drug conjugate.
Researchers combine 3D printing and robotic surgery with advanced manufacturing. Credit: 2017 Royal Melbourne Institute of Technology.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.